The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease
Open accessAbstract
To provide evidence‐based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non‐motor complications, either disease‐related (e.g. freezing) or treatment‐related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non‐European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (‘good practice point’) is made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Self-citation(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Low, P. A. (1997) · JAMA · doi:10.1001/jama.1997.03540370036033 · Cited by 425
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine
Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., Rubin, M., & Fouad-Tarazi, F. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90230-m · Cited by 396
Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism
Santamaria, J., Tolosa, E., & Valles, A. (1986) · Neurology · doi:10.1212/wnl.36.8.1130 · Cited by 233
Self-citationBurn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
Suicide after successful deep brain stimulation for movement disorders
Burkhard, P. R., Vingerhoets, F. J. G., Berney, A., Bogousslavsky, J., Villemure, J.-G., & Ghika, J. (2004) · Neurology · doi:10.1212/01.wnl.0000145603.48221.b5 · Cited by 219
Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005) · Movement Disorders · doi:10.1002/mds.20555 · Cited by 191 · cited 2×
“Although the use of SSRIs in PD-associated depression has been reported as beneficial in numerous small, open-label studies covering a variety of agents (fluoxetine, sertraline, paroxetine; class II–IV: see [170] for review), to date only one small double-blind placebocontrolled study of sertraline has assessed this a…”
Background
Cited by
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Self-citationRandomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations
Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M., Chirilineau, D., Stocchi, F., Lucini, V., Giuliani, R., Forrest, E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25751 · Cited by 293
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Stacy, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0424-5 · Cited by 66
A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease
Ceravolo, R., Rossi, C., Del Prete, E., & Bonuccelli, U. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1130128 · Cited by 44
Self-citation
Metadata
- Authors
- Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., Rascol, O., & Sampaio, C.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-10-13
- Volume
- 13
- Issue
- 11
- Pages
- 1186-1202
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W4211004647
- Cited by
- 173
- References
- 9
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease. https://app.cochat.ai/papers/10.1111/j.1468-1331.2006.01548.x
- The paper
- Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., Rascol, O., & Sampaio, C. (2006). Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2006.01548.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
